WB, IP
H Mk Dg
Endogenous
75
Rabbit
#Q9UKV5
267
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Monkey, Dog
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human AMFR protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Autocrine motility factor receptor (AMFR/gp78) is a putative seven transmembrane domain G protein-coupled receptor that functions, in part, at the cell surface as a cytokine receptor for autocrine motility factor/phosphoglucose isomerase (AMF/PGI). AMFR is also localized to an intracellular mitochondria-associated smooth ER domain where it functions as an E3 ubiquitin ligase (1). AMFR function, as both a cytokine receptor and ubiquitin ligase, is linked to a variety of cellular signaling cascades associated with metastasis development and increased invasiveness. AMFR was initially proposed to be a RING-H2 E3 ubiquitin ligase after sequence analysis identified a catalytic RING finger and CUE motif, which are responsible for ubiquitin ligase activity and ubiquitin binding, respectively (2,3). Indeed, AMFR is a key component and amongst the best characterized ubiquitin ligases of the endoplasmic reticulum associated degradation (ERAD) machinery, a process involving recognition of misfolded proteins, ubiquitination, deglycosylation, retro-translocation to the cytosol, and targeting to the proteasome (4). Recent studies have shown that AMFR plays an important role in cholesterol homeostasis via the sterol-mediated ubiquitination of HMG-CoA reductase and its cofactor Insig-1 (5,6). Furthermore, AMFR has been implicated in the degradation of apolipoprotein B100 (7). It was recently reported that AMFR degrades the metastasis suppressor KAI-1/CD-82, representing the first evidence that AMFR ubiquitin ligase activity is involved in metastasis development (8). Increased expression of AMFR correlates with a high incidence of recurrence and reduced survival in patients with bladder, colorectal, and gastric cancers (9-11).
- Registre, M. et al. (2004) Biochem Biophys Res Commun 320, 1316-22.
- Shimizu, K. et al. (1999) FEBS Lett 456, 295-300.
- Ponting, C.P. (2000) Biochem J 351 Pt 2, 527-35.
- Meusser, B. et al. (2005) Nat Cell Biol 7, 766-72.
- Song, B.L. et al. (2005) Mol Cell 19, 829-40.
- Lee, J.N. et al. (2006) J Biol Chem 281, 39308-15.
- Liang, J.S. et al. (2003) J Biol Chem 278, 23984-8.
- Tsai, Y.C. et al. (2007) Nat Med 13, 1504-9.
- Hirono, Y. et al. (1996) Br J Cancer 74, 2003-7.
- Nakamori, S. et al. (1994) Cancer 74, 1855-62.
- Otto, T. et al. (1997) Am J Pathol 150, 1919-23.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.